World's Best Scientists 2026 revealed!
Frédérique Penault-Llorca

Frédérique Penault-Llorca

D-Index & Metrics

Medicine

D-Index
109
Citations
73928
World Ranking
5658
National Ranking
164

Overview

Frédérique Penault-Llorca is affiliated with the University of Clermont Auvergne in France. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology, and Genetics.

Their work concentrates on several main research topics, including Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, and Cancer Treatment and Pharmacology.

Frequent co-authors collaborating with Frédérique Penault-Llorca include:

  • Giuseppe Curigliano
  • Fabrice André
  • Fátima Cardoso
  • Nadia Harbeck
  • Anne-Vibeke Lænkholm

Their publications have appeared frequently in scientific journals such as:

  • Annals of Oncology
  • Cancer Research
  • Cancers
  • ESMO Open
  • Journal of Clinical Oncology

Selected recent papers authored or co-authored by Frédérique Penault-Llorca include:

  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5), 2020, Annals of Oncology
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, 2021, Annals of Oncology
  • HER2-Low Breast Cancer: Pathological and Clinical Landscape, 2020, Journal of Clinical Oncology
  • Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group, 2020, JNCI Journal of the National Cancer Institute
  • ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer, 2023, Annals of Oncology

Best Publications

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    R. Salgado;C. Denkert;S. Demaria;N. Sirtaine

  • KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

    Astrid Lièvre;Jean-Baptiste Bachet;Delphine Le Corre;Valérie Boige

  • Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

    Mitch Dowsett;Torsten O. Nielsen;Roger A’Hern;John Bartlett

  • KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

    Astrid Lièvre;Jean-Baptiste Bachet;Valérie Boige;Anne Cayre

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    E. Senkus;S. Kyriakides;F. Penault-Llorca;P. Poortmans

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

    Antonella Sistigu;Takahiro Yamazaki;Erika Vacchelli;Kariman Chaba

  • Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

    Fabrice Barlesi;Julien Mazieres;Jean-Philippe Merlio;Didier Debieuvre

  • Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

    Pierre Laurent-Puig;Anne Cayre;Gilles Manceau;Emmanuel Buc

  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

    Elizabeth A Mittendorf;Hong Zhang;Carlos H Barrios;Shigehira Saji

  • Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

    Sunil R. Lakhani;Jorge S. Reis-Filho;Laura Fulford;Frederique Penault-Llorca

  • Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

    F. Cardoso;A. Costa;L. Norton;E. Senkus

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

    Frédéric Bibeau;Evelyne Lopez-Crapez;Frédéric Di Fiore;Simon Thezenas

  • Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

    L. Arnould;M. Gelly;F. Penault-Llorca;L. Benoit

  • An International Ki67 Reproducibility Study

    Mei Yin C Polley;Samuel C Y Leung;Lisa M. McShane;Dongxia Gao

Frequent Co-Authors

Yves-Jean Bignon
Yves-Jean Bignon Centre Jean Perrin
Giuseppe Viale
Giuseppe Viale University of Milan
Jocelyne Jacquemier
Jocelyne Jacquemier Grenoble Alpes University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Roberto Salgado
Roberto Salgado Peter MacCallum Cancer Centre
Torsten O. Nielsen
Torsten O. Nielsen University of British Columbia
Giuseppe Curigliano
Giuseppe Curigliano University of Milan
Carsten Denkert
Carsten Denkert Philipp University of Marburg
Pierre Laurent-Puig
Pierre Laurent-Puig Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens the door to numerous online degrees and healthcare career pathways. Whether you’re looking to support mental health or take on leadership roles in healthcare, accredited online programs offer flexibility and accessibility.

For those interested in mental health, online pmhnp programs provide a direct route to advanced practice as a Psychiatric Mental Health Nurse Practitioner. If you’re interested in healthcare management, consider pursuing a bachelors in health administration, which equips you with foundational knowledge in healthcare operations, policy, and leadership.

Many professionals enhance their qualifications with affordable mha online programs, designed for those who wish to advance into executive or administrative roles. Alternatively, nurses seeking to reach the highest level of clinical practice can enroll in the best online bsn to dnp programs, combining research, leadership, and specialized clinical training for top-tier positions.

With these flexible, accredited options, you can tailor your educational journey to your career goals in the rapidly evolving healthcare field.

Best Scientists Citing Frédérique Penault-Llorca

Trending Scientists

Recently Published Articles